$YTENQ
YIELD10 BIOSCIENCE, INC. Stock $ytenq

$ytenq Overview Financials Valuation SEC Filings Company Website

2013 Q1 Form 10-Q Financial Statement

#000110465913040195 Filed on May 10, 2013

Income Statement

Concept	2013 Q1	2012 Q1	2010
Revenue	$1.251M	$39.32M	$448.0K
YoY Change	-96.82%	11961.96%	-68.56%
Cost Of Revenue	$557.0K	$55.00K	$23.67M
YoY Change	912.73%		-3.27%
Gross Profit	$694.0K	$39.27M	-$23.23M
YoY Change	-98.23%	11799.09%	0.78%
Gross Profit Margin	55.48%	99.86%	-5185.27%
Selling, General & Admin	$3.312M	$3.980M	$15.71M
YoY Change	-16.78%	5.01%	0.2%
% of Gross Profit	477.23%	10.14%
Research & Development	$4.860M	$6.050M
YoY Change	-19.67%	-2.42%
% of Gross Profit	700.29%	15.41%
Depreciation & Amortization	$295.0K	$379.0K	$1.647M
YoY Change	-22.16%	-0.26%	-39.76%
% of Gross Profit	42.51%	0.97%
Operating Expenses	$3.312M	$10.02M	$15.71M
YoY Change	-66.95%	0.3%	0.2%
Operating Profit	-$6.731M	$28.82M	-$38.94M
YoY Change	-123.35%	-398.37%	0.54%
Interest Expense	$10.00K	$17.00K	$136.0K
YoY Change	-41.18%	-15.0%	-82.38%
% of Operating Profit		0.06%
Other Income/Expense, Net	$22.00K
YoY Change
Pretax Income	-$6.760M	$28.84M	-$38.80M
YoY Change	-123.44%	-399.17%	2.21%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income		0.0%
Net Earnings	-$6.760M	$28.84M	-$38.80M
YoY Change	-123.44%	-399.17%	2.21%
Net Earnings / Revenue	-540.37%	73.34%	-8660.71%
Basic Earnings Per Share	-$0.20	$0.84	-$1.45
Diluted Earnings Per Share	-$0.20	$0.84	-$1.45
COMMON SHARES
Basic Shares Outstanding	34.35M shares	34.14M shares	26.77M shares
Diluted Shares Outstanding	34.35M shares	34.27M shares	26.77M shares

Balance Sheet

Concept	2013 Q1	2012 Q1	2010
SHORT-TERM ASSETS
Cash & Short-Term Investments	$37.70M	$66.00M	$61.60M
YoY Change	-42.88%	27.17%	-33.19%
Cash & Equivalents	$20.51M	$9.604M	$12.50M
Short-Term Investments	$17.20M	$56.30M	$49.00M
Other Short-Term Assets	$700.0K	$700.0K	$800.0K
YoY Change	0.0%	0.0%	0.0%
Inventory	$3.624M	$3.000M
Prepaid Expenses
Receivables	$777.0K	$700.0K	$800.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$43.75M	$70.40M	$63.30M
YoY Change	-37.85%	30.86%	-32.23%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.120M	$2.000M	$2.800M
YoY Change	-44.0%	-25.93%	-20.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$0.00	$0.00	$0.00
YoY Change
Other Assets	$95.00K	$700.0K	$700.0K
YoY Change	-86.43%	0.0%	0.0%
Total Long-Term Assets	$1.809M	$2.700M	$3.500M
YoY Change	-33.0%	-20.59%	-16.67%
TOTAL ASSETS
Total Short-Term Assets	$43.75M	$70.40M	$63.30M
Total Long-Term Assets	$1.809M	$2.700M	$3.500M
Total Assets	$45.56M	$73.10M	$66.80M
YoY Change	-37.67%	27.8%	-31.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$92.00K	$200.0K	$200.0K
YoY Change	-54.0%		-66.67%
Accrued Expenses	$2.679M	$2.700M	$4.100M
YoY Change	-0.78%	-3.57%	10.81%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.908M	$3.300M	$6.400M
YoY Change	18.42%	-32.65%	39.13%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$134.0K	$300.0K	$36.70M
YoY Change	-55.33%	-99.18%	-3.17%
Total Long-Term Liabilities	$134.0K	$300.0K	$36.70M
YoY Change	-55.33%	-99.18%	-3.17%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.908M	$3.300M	$6.400M
Total Long-Term Liabilities	$134.0K	$300.0K	$36.70M
Total Liabilities	$4.056M	$3.600M	$43.10M
YoY Change	12.67%	-91.39%	1.41%
SHAREHOLDERS EQUITY
Retained Earnings	-$248.8M
YoY Change
Common Stock	$290.3M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$41.51M	$69.50M	$23.70M
YoY Change
Total Liabilities & Shareholders Equity	$45.56M	$73.10M	$66.80M
YoY Change	-37.67%	27.8%	-31.56%

Cashflow Statement

Concept	2013 Q1	2012 Q1	2010
OPERATING ACTIVITIES
Net Income	-$6.760M	$28.84M	-$38.80M
YoY Change	-123.44%	-399.17%	2.21%
Depreciation, Depletion And Amortization	$295.0K	$379.0K	$1.647M
YoY Change	-22.16%	-0.26%	-39.76%
Cash From Operating Activities	-$8.500M	-$12.26M	-$32.00M
YoY Change	-30.67%	30.98%	24.22%
INVESTING ACTIVITIES
Capital Expenditures	$64.00K	$148.0K	$906.0K
YoY Change	-56.76%	-146.25%	-55.08%
Acquisitions
YoY Change
Other Investing Activities	$14.51M	$720.0K	$32.28M
YoY Change	1915.28%	-95.8%	-291.69%
Cash From Investing Activities	$14.44M	$570.0K	$31.38M
YoY Change	2433.33%	-96.62%	-266.38%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	10.00K	10.00K	2.340M
YoY Change	0.0%	-75.0%	-91.99%
NET CHANGE
Cash From Operating Activities	-8.500M	-12.26M	-32.00M
Cash From Investing Activities	14.44M	570.0K	31.38M
Cash From Financing Activities	10.00K	10.00K	2.340M
Net Change In Cash	5.950M	-11.68M	1.720M
YoY Change	-150.94%	-255.11%	-111.18%
FREE CASH FLOW
Cash From Operating Activities	-$8.500M	-$12.26M	-$32.00M
Capital Expenditures	$64.00K	$148.0K	$906.0K
Free Cash Flow	-$8.564M	-$12.41M	-$32.91M
YoY Change	-30.98%	37.26%	18.46%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2012Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	34136333	shares
CY2012Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	34265638	shares
CY2013Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.65
CY2013Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Use of Estimates</font></b></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 26pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 26pt;"> </p> </div>
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	261915	shares
CY2013Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6763000	USD
CY2012Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	28840000	USD
CY2013Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	34353277	shares
CY2012Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	129305	shares
CY2012Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	129305	shares
CY2013Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	34353277	shares
CY2013Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5741056	shares
CY2012Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4338168	shares
CY2013Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	863000	USD
CY2012Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1122000	USD
CY2013Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	4951000	USD
CY2013Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y2M12D
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5579042	shares
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5736970	shares
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	9.01
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.19
CY2013Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	3175	shares
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3186670	shares
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.68
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.49
CY2013Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.68
CY2012Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.87	pure
CY2013Q1	dei	Entity Registrant Name EntityRegistrantName	METABOLIX, INC.
CY2012Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.85	pure
CY2013Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001121702
CY2013Q1	dei	Document Type DocumentType	10-Q
CY2013Q1	dei	Document Period End Date DocumentPeriodEndDate	2013-03-31
CY2013Q1	dei	Amendment Flag AmendmentFlag	false
CY2013Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2013Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2013Q1	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2013Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
CY2013Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2013Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	34446953	shares
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20512000	USD
CY2013Q1	us-gaap	Short Term Investments ShortTermInvestments	17197000	USD
CY2012Q4	us-gaap	Short Term Investments ShortTermInvestments	29201000	USD
CY2013Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	777000	USD
CY2012Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	839000	USD
CY2013Q1	mblx	Research And Development Revenue ResearchAndDevelopmentRevenue	380000	USD
CY2012Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	75000	USD
CY2013Q1	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	933000	USD
CY2012Q4	us-gaap	Unbilled Contracts Receivable UnbilledContractsReceivable	372000	USD
CY2013Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	710000	USD
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	692000	USD
CY2013Q1	us-gaap	Inventory Net InventoryNet	3624000	USD
CY2012Q4	us-gaap	Inventory Net InventoryNet	3204000	USD
CY2013Q1	us-gaap	Assets Current AssetsCurrent	43753000	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	48955000	USD
CY2013Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	594000	USD
CY2012Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	594000	USD
CY2013Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1120000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1358000	USD
CY2012Q4	us-gaap	Long Term Investments LongTermInvestments	2508000	USD
CY2013Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	95000	USD
CY2012Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	95000	USD
CY2013Q1	us-gaap	Assets Assets	45562000	USD
CY2012Q4	us-gaap	Assets Assets	53510000	USD
CY2013Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	92000	USD
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1233000	USD
CY2013Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2679000	USD
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3519000	USD
CY2013Q1	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	165000	USD
CY2012Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	165000	USD
CY2013Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	972000	USD
CY2012Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1067000	USD
CY2013Q1	us-gaap	Liabilities Current LiabilitiesCurrent	3908000	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5984000	USD
CY2013Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	14000	USD
CY2012Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	55000	USD
CY2013Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	134000	USD
CY2012Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	131000	USD
CY2013Q1	us-gaap	Liabilities Liabilities	4056000	USD
CY2012Q4	us-gaap	Liabilities Liabilities	6170000	USD
CY2013Q1	mblx	License And Royalty Revenue LicenseAndRoyaltyRevenue	49000	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-242032000	USD
CY2013Q1	us-gaap	Stockholders Equity StockholdersEquity	41506000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	47340000	USD
CY2013Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2012Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q1	us-gaap	Common Stock Value CommonStockValue	344000	USD
CY2013Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	290000000	USD
CY2012Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	289050000	USD
CY2013Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.20
CY2012Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.84
CY2013Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-43000	USD
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-21000	USD
CY2013Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-248795000	USD
CY2013Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	45562000	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	53510000	USD
CY2013Q1	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2013Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2013Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2013Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2012Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2013Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2013Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	34365227	shares
CY2013Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	34365227	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	34306570	shares
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	34306570	shares
CY2012Q1	mblx	Revenue From Termination Of Collaboration With Subsidiary RevenueFromTerminationOfCollaborationWithSubsidiary	38885000	USD
CY2013Q1	us-gaap	Revenue From Grants RevenueFromGrants	724000	USD
CY2012Q1	us-gaap	Revenue From Grants RevenueFromGrants	378000	USD
CY2013Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	790000	USD
CY2012Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	14000	USD
CY2013Q1	us-gaap	Sales Revenue Net SalesRevenueNet	1943000	USD
CY2012Q1	us-gaap	Sales Revenue Net SalesRevenueNet	39322000	USD
CY2013Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	557000	USD
CY2012Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	55000	USD
CY2013Q1	mblx	Cost Of Revenue Research And Development Expenses CostOfRevenueResearchAndDevelopmentExpenses	4859000	USD
CY2012Q1	mblx	Cost Of Revenue Research And Development Expenses CostOfRevenueResearchAndDevelopmentExpenses	6045000	USD
CY2013Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3312000	USD
CY2013Q1	us-gaap	Costs And Expenses CostsAndExpenses	8728000	USD
CY2012Q1	us-gaap	Costs And Expenses CostsAndExpenses	10499000	USD
CY2013Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	10000	USD
CY2012Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	17000	USD
CY2013Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.20
CY2012Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.84
CY2013Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-7000	USD
CY2012Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-13000	USD
CY2013Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1155000	USD
CY2013Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-15000	USD
CY2012Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	2000	USD
CY2013Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-22000	USD
CY2012Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-11000	USD
CY2013Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6785000	USD
CY2012Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	28829000	USD
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-6785000	USD
CY2012Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	28823000	USD
CY2013Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	295000	USD
CY2012Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	379000	USD
CY2013Q1	mblx	Charge For Company Common Stock Match ChargeForCompanyCommonStockMatch	180000	USD
CY2012Q1	mblx	Charge For Company Common Stock Match ChargeForCompanyCommonStockMatch	162000	USD
CY2013Q1	us-gaap	Share Based Compensation ShareBasedCompensation	863000	USD
CY2012Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1104000	USD
CY2013Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-62000	USD
CY2012Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-87000	USD
CY2013Q1	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	561000	USD
CY2012Q1	us-gaap	Increase Decrease In Unbilled Receivables IncreaseDecreaseInUnbilledReceivables	240000	USD
CY2013Q1	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	-75000	USD
CY2012Q1	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	-175000	USD
CY2013Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	18000	USD
CY2012Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-114000	USD
CY2013Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	420000	USD
CY2012Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2977000	USD
CY2013Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1141000	USD
CY2012Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-323000	USD
CY2013Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-937000	USD
CY2012Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-885000	USD
CY2013Q1	mblx	Increase Decrease In Deferred Rent And Other Long Term Liabilities IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities	-38000	USD
CY2012Q1	mblx	Increase Decrease In Deferred Rent And Other Long Term Liabilities IncreaseDecreaseInDeferredRentAndOtherLongTermLiabilities	-39000	USD
CY2013Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-95000	USD
CY2012Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-38656000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-8498000	USD
CY2012Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-12259000	USD
CY2013Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	64000	USD
CY2012Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	148000	USD
CY2013Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	5015000	USD
CY2012Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	28240000	USD
CY2013Q1	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	19520000	USD
CY2012Q1	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	28961000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	14441000	USD
CY2012Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	573000	USD
CY2013Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	5000	USD
CY2012Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	11000	USD
CY2013Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	-8000	USD
CY2012Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	2000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	5940000	USD
CY2012Q1	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-11673000	USD
CY2013Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1079000	USD
CY2013Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	313000	USD
CY2013Q1	mblx	Accrued Intellectual Property Current AccruedIntellectualPropertyCurrent	132000	USD
CY2012Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2379000	USD
CY2012Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	301000	USD
CY2012Q4	mblx	Accrued Intellectual Property Current AccruedIntellectualPropertyCurrent	105000	USD
CY2012Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	734000	USD
CY2012	us-gaap	Segment Reporting Information Revenue SegmentReportingInformationRevenue	42316000	USD
CY2012	us-gaap	Sales Revenue Net SalesRevenueNet	42316000	USD
CY2011	us-gaap	Segment Reporting Information Revenue SegmentReportingInformationRevenue	1425000	USD
CY2011	us-gaap	Sales Revenue Net SalesRevenueNet	1425000	USD
CY2010	us-gaap	Segment Reporting Information Revenue SegmentReportingInformationRevenue	448000	USD
CY2010	us-gaap	Sales Revenue Net SalesRevenueNet	448000	USD
CY2013Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	615000	USD
CY2013Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	36000	USD
CY2013Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2973000	USD
CY2012Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	640000	USD
CY2012Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	2000	USD
CY2012Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2562000	USD
CY2013Q1	us-gaap	Restructuring And Related Cost Cost Incurred To Date RestructuringAndRelatedCostCostIncurredToDate	859000	USD
CY2013Q1	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	34840000	USD
CY2013Q1	us-gaap	Availableforsale Securities Gross Unrealized Gain AvailableforsaleSecuritiesGrossUnrealizedGain	6000	USD
CY2013Q1	us-gaap	Available For Sale Securities Fair Value Disclosure AvailableForSaleSecuritiesFairValueDisclosure	34846000	USD
CY2012Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	31696000	USD
CY2012Q4	us-gaap	Availableforsale Securities Gross Unrealized Gain AvailableforsaleSecuritiesGrossUnrealizedGain	13000	USD
CY2012Q4	us-gaap	Available For Sale Securities Fair Value Disclosure AvailableForSaleSecuritiesFairValueDisclosure	31709000	USD
CY2013Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2012Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2013Q1	mblx	Maximum Period To Audit For Loss MaximumPeriodToAuditForLoss	P3Y
CY2013Q1	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2012Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2012Q4	mblx	Operating Loss Carryforwards Attributable To Deduction Related To Exercise Of Stock Options OperatingLossCarryforwardsAttributableToDeductionRelatedToExerciseOfStockOptions	19213000	USD
CY2012Q4	us-gaap	Undistributed Earnings Of Foreign Subsidiaries UndistributedEarningsOfForeignSubsidiaries	252000	USD
CY2013Q1	us-gaap	Deferred Tax Liabilities Undistributed Foreign Earnings DeferredTaxLiabilitiesUndistributedForeignEarnings	0	USD
CY2013Q1	us-gaap	Dilutive Securities DilutiveSecurities	0	USD
CY2013Q1	mblx	Provision For Income Taxes For Undistributed Earnings Of Foreign Subsidiaries ProvisionForIncomeTaxesForUndistributedEarningsOfForeignSubsidiaries	0	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21277000	USD
CY2012Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9604000	USD
CY2012Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0072	pure
CY2012Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0115	pure
CY2013Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Concentration of Credit Risk</font></b></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 27pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash and cash equivalents and short-term investments. The Company primarily invests its excess cash and cash equivalents in money market funds, corporate debt, federal agency notes and U.S. treasury notes. Investments are acquired in accordance with the Company’s investment policy which establishes a concentration limit per issuer.</font></p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 27pt;"> </p> <p style="MARGIN: 0in 0in 0pt; TEXT-INDENT: 27pt;"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman;" size="2">The Company provides credit to customers in the normal course of business. The Company performs ongoing credit evaluations of its customers’ financial condition and limits the amount of credit extended when deemed necessary. At March 31, 2013, the Company’s accounts and unbilled receivables include $758 or 44% from U.S. and Canadian government grants and $638 or 37% from customer product sales. At December 31, 2012, the Company’s accounts and unbilled receivables include $561 or 46% from U.S. and Canadian government grants and $535 or 44% from customer product sales. At March 31, 2013 and December 31, 2012, one customer represented 39% and 41%, respectively, of accounts receivable due from product sales.</font></p> <p style="MARGIN: 0in 0in 0pt;"> </p> </div>
CY2013Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y11M12D
CY2013Q1	us-gaap	Segment Reporting Information Revenue SegmentReportingInformationRevenue	1943000	USD
CY2012Q1	us-gaap	Segment Reporting Information Revenue SegmentReportingInformationRevenue	39322000	USD
CY2013Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	12000	USD
CY2012Q1	mblx	License And Royalty Revenue LicenseAndRoyaltyRevenue	45000	USD
CY2013Q1	us-gaap	Investments And Cash InvestmentsAndCash	37709000	USD
CY2013Q1	mblx	Minimum Period For Which Cash Cash Equivalents Investments And Cash From Expected Product Sales Is Sufficient To Meet Projected Operating Requirements MinimumPeriodForWhichCashCashEquivalentsInvestmentsAndCashFromExpectedProductSalesIsSufficientToMeetProjectedOperatingRequirements	P12M
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	42126	shares
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	58686	shares
CY2013Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	3.67
CY2013Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	5.30
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0092	pure
CY2013Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.85	pure
CY2013Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	item
CY2013Q1	us-gaap	Restructuring Reserve RestructuringReserve	0	USD
CY2013Q1	us-gaap	Deferred Revenue DeferredRevenue	508000	USD
CY2012Q4	us-gaap	Deferred Revenue DeferredRevenue	257000	USD

Files In Submission

Name	View Source	Status
0001104659-13-040195-index-headers.html	Edgar Link	pending
0001104659-13-040195-index.html	Edgar Link	pending
0001104659-13-040195.txt	Edgar Link	pending
0001104659-13-040195-xbrl.zip	Edgar Link	pending
a13-8554_110q.htm	Edgar Link	pending
a13-8554_1ex31d1.htm	Edgar Link	pending
a13-8554_1ex31d2.htm	Edgar Link	pending
a13-8554_1ex32d1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
mblx-20130331.xml	Edgar Link	completed
mblx-20130331.xsd	Edgar Link	pending
mblx-20130331_cal.xml	Edgar Link	unprocessable
mblx-20130331_def.xml	Edgar Link	unprocessable
mblx-20130331_lab.xml	Edgar Link	unprocessable
mblx-20130331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$YTENQ
YIELD10 BIOSCIENCE, INC. Stock $ytenq

2013 Q1 Form 10-Q Financial Statement

#000110465913040195 Filed on May 10, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$YTENQ YIELD10 BIOSCIENCE, INC. Stock $ytenq

2013 Q1 Form 10-Q Financial Statement

#000110465913040195 Filed on May 10, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$YTENQ
YIELD10 BIOSCIENCE, INC. Stock $ytenq